Phase 1/2Completed

An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread (CheckMate 9N9)

A Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal Cancers

Sponsor
Bristol-Myers Squibb (Industry)
Enrollment
325 enrolled
Conditions
Colorectal Cancer; Colorectal Tumors; Colorectal Carcinoma; Colorectal Neoplasm
Interventions
Nivolumab; Trametinib; Ipilimumab; Regorafenib
Ages
adults, older adults
Registry
NCT03377361, EUCTR2017-001830-24

Full record on ClinicalTrials.gov

From the registry

The purpose of this study is to investigate treatment with nivolumab in combination with trametinib with or without ipilimumab in participants with previously treated cancer of the colon or rectum that has spread.

Primary outcomes

  • Dose Limiting Toxicities in Part 1 and Part 1A
  • Safety Related Events in Part 1 and Part 1 A
  • Clinical Laboratory Abnormalities in Part 1 and Part 1A: Specific Thyroid Tests
  • Clinical Laboratory Abnormalities in Part 1 and Part 1A: Specific Liver Tests

History

  1. Results first posted

  2. Last registry update

  3. Primary completion

  4. Started

  5. Registered